CJC-1295 — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

CJC-1295

Also known as: CJC1295, GRF(1-29) analog, hGRF(1-29) albumin bioconjugate, long-acting GHRH analog, DAC:GRF

Growth Hormone-Releasing Hormone (GHRH) Analogue / Growth Hormone Secretagogue

Not FDA-approvedLast updated: November 4, 2026Based on 19 peer-reviewed studies

What it is

CJC-1295 is a peptide people use to raise their growth hormone levels for muscle building, fat loss, and recovery. It works by extending the action of a natural hormone that tells the pituitary to release growth hormone. Not FDA-approved; banned by WADA; classified as a prohibited performance-enhancing substance.

The scientific side

CJC-1295 is a synthetic analogue of human growth hormone-releasing hormone (GHRH/hGRF 1-29). It incorporates a reactive maleimidopropionic acid group (Drug Affinity Complex, DAC) at its C-terminus that allows covalent binding to free thiols on endogenous plasma proteins, primarily serum albumin (Cys34), markedly extending its plasma half-life to approximately 5.8–8.1 days in humans. By acting as a long-lasting GHRH receptor agonist at anterior pituitary somatotrophs, CJC-1295 stimulates dose-dependent increases in GH secretion and downstream IGF-1 production. GH pulsatility is preserved, but trough (basal) GH levels are markedly elevated, which appears to drive the observed increases in IGF-1. In rodent models, CJC-1295 has been shown to activate IGF-1 signalling and satellite cell repair pathways, rescue growth deficits in GHRH-knockout mice by promoting somatotroph proliferation, and restore normal pituitary size, GH, and IGF-1 levels in brain-specific M3 muscarinic receptor knockout mice. It demonstrates enhanced in vitro stability against dipeptidylpeptidase-IV compared to native GHRH. This entry covers the DAC form only. CJC-1295 without DAC (Mod GRF 1-29) has its own entry: the same tetrasubstituted GRF(1-29) peptide without the DAC group, so it does not bind albumin, has a half-life of roughly 30 minutes, and is dosed 1-3 times daily rather than weekly.

Class: Growth Hormone-Releasing Hormone (GHRH) Analogue / Growth Hormone Secretagogue

Not FDA-approvedLow researchHormonesLong-acting GHRH analog (DAC-modified)

At a glance

What it isA modified GRF(1-29) with a chemical "drug affinity complex" (DAC) that latches onto albumin in the blood, so one injection lasts about a week.
FDA statusNot approved for any use. In December 2024 an FDA advisory committee voted 0-13 against letting compounding pharmacies make it.
Used forRaising growth hormone and IGF-1 with a once-weekly injection.
Human evidenceTwo small 2006 studies in healthy adults; a phase 2 trial in HIV was terminated in 2006.
Half-lifeAbout 6-8 days (5.8-8.1 days in healthy adults).
Banned in sportYes. WADA names CJC-1295 under S2.2.4, prohibited at all times.

What is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone. Its core is a "tetrasubstituted" GRF(1-29), the same 29-amino-acid sequence as Sermorelin with four amino acids swapped, plus a reactive group attached at the end. That group, the drug affinity complex (DAC), bonds to albumin in the blood after injection.

The name causes confusion. In research papers "CJC-1295" means the DAC version. Vendors also sell "CJC-1295 without DAC", which is the same backbone without the albumin anchor and is better known as Mod GRF 1-29. They behave very differently.

Sources: [1] [2]

How does it work?

Like natural GHRH, CJC-1295 binds GHRH receptors on the pituitary and triggers growth hormone release, which raises IGF-1. Bonding to albumin protects it from breakdown and keeps it circulating for days instead of minutes.

A study in healthy young men found that growth hormone kept its natural pulses a week after a single dose: trough and average levels rose, but pulsatility was preserved.

Pharmacokinetics

Half-life5.8-8.1 days (healthy adults, subcutaneous)
MetabolismBonds to albumin (cysteine 34) after injection, which protects it from enzyme breakdown
ClearanceNot characterized in humans
RouteSubcutaneous injection; studied as single, weekly and every-other-week doses

Sources: [1] [3] [2]

Is it FDA-approved?

No. CJC-1295 has never been approved for any use.

FDA lists it among bulk substances that may present significant safety risks in compounding, noting immunogenicity and impurity concerns and that "FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction." As of April 2026 it appears under "nominated but withdrawn".

In December 2024, FDA's Pharmacy Compounding Advisory Committee voted against adding any CJC-1295 form to the 503A bulks list: 0-13 for each DAC form and for the free base, and 1-12 for the acetate.

  • WADA: S2.2.4 Growth hormone releasing factors (named among GHRH analogues; prohibited at all times)

Sources: [4] [5]

History

CJC-1295 came out of ConjuChem, a Montreal biotech that attached peptides to albumin to make them last longer. A 2005 rat study picked CJC-1295 from several candidates because it stayed in plasma beyond 72 hours.

In 2006 two studies in healthy adults showed growth hormone and IGF-1 stayed raised for days after one injection. A phase 2 trial in people with HIV and excess visceral fat started in December 2005 and was terminated in 2006. ConjuChem filed for bankruptcy in 2010. By then CJC-1295 was already turning up in unlabeled products seized by anti-doping labs.

Sources: [1] [2] [6] [7] [8]

Regulatory timeline

  1. By September 2024FDA lists CJC-1295 among other bulk drug substances that may present significant safety risks, citing increased heart rate and a systemic vasodilatory reaction. Source
  2. December 4, 2024FDA's Pharmacy Compounding Advisory Committee votes against all CJC-1295 forms for the 503A bulks list: 0-13 for the DAC forms and free base, 1-12 for the acetate. Source
  3. April 2026FDA's page lists CJC-1295 under "nominated but withdrawn". Source
  4. As of October 2026Still not FDA-approved. It was not on the July 2026 advisory committee agenda. Source

Side effects

In the 2006 dose-finding studies, CJC-1295 was "safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg". FDA separately notes serious adverse events including increased heart rate and a systemic vasodilatory reaction (flushing and blood vessel widening).

Because each dose keeps growth hormone and IGF-1 raised for more than a week, effects can't be stopped quickly after an injection. Long-term safety has not been studied.

Who should not use it

  • No established contraindications: CJC-1295 never completed development.
  • Competitive athletes: Prohibited at all times under WADA S2.2.4 (growth hormone releasing factors), per the 2026 World Anti-Doping Code Prohibited List. Verified against the current WADA list as of October 2026.
  • Active cancer: it raises growth hormone and IGF-1, growth factors that approved GH-releasing drugs list as a contraindication.
  • Heart rhythm or blood pressure problems: FDA notes increased heart rate and vasodilatory reactions.

Two 2006 dose-finding trials in healthy adults; FDA safety notes on its compounding risk page.

Sources: [2] [4]

What does the research show?

In two randomized, placebo-controlled trials in healthy adults aged 21-61, a single injection raised average growth hormone 2- to 10-fold for 6 days or more, and IGF-1 1.5- to 3-fold for 9-11 days. After repeated weekly or every-other-week doses, IGF-1 stayed above baseline for up to 28 days. The estimated half-life was 5.8-8.1 days.

These were short studies of hormone levels in healthy people. No published trial has measured muscle, fat, sleep or other outcomes people use it for, and the doses commonly used online are below the doses studied.

Studied for

  • Growth hormone and IGF-1 levels in healthy adults (2006 trials)
  • Visceral fat in HIV (phase 2, terminated 2006)
  • Growth hormone release and plasma persistence in rats (animal study)

Sources: [2] [3] [9]

FAQ

Is CJC-1295 the same as Mod GRF 1-29?

No. Both share the same modified GRF(1-29) backbone, but CJC-1295 adds a DAC group that binds albumin and lasts about a week. Mod GRF 1-29 (sold as "CJC-1295 without DAC") lasts minutes.

Sources: [1]

How long does CJC-1295 last?

Its half-life was 5.8-8.1 days in healthy adults, and one injection kept IGF-1 raised for 9-11 days.

Sources: [2]

Is CJC-1295 FDA-approved?

No. Its developer stopped before approval, and in 2024 an FDA advisory committee voted 0-13 against compounding the DAC forms.

Sources: [5]

Does CJC-1295 stop natural growth hormone pulses?

Not in the one study that checked: a week after a dose, growth hormone was higher but still pulsatile.

Sources: [3]

What side effects has FDA noted?

FDA cites serious adverse events including increased heart rate and a systemic vasodilatory reaction, and says clinical data are limited.

Sources: [4]

Is CJC-1295 banned in sport?

Yes. The 2026 WADA Prohibited List names CJC-1295 under S2.2.4, prohibited at all times.

Sources: [10]

Was CJC-1295 tested for muscle or fat loss?

Not in any published trial. A phase 2 trial of visceral fat in HIV was terminated in 2006 without published results.

Sources: [6]

Citations

  1. Jetté L, et al. hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005. PMID 15817669
  2. Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006. PMID 16352683
  3. Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab 2006. PMID 17018654
  4. FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  5. FDA: final summary minutes of the Pharmacy Compounding Advisory Committee meeting, December 4, 2024. fda.gov/media/185642/download
  6. NCT00267527: Phase 2 study of CJC 1295 for 12 weeks in HIV-infected patients with HIV-associated visceral obesity (ConjuChem; terminated). clinicaltrials.gov/study/NCT00267527
  7. ConjuChem announces Bankruptcy Act filing. Newswire, 2010. newswire.ca/news-releases/conjuchem-announces-bankruptcy-act-filing-544815902.html
  8. Henninge J, et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal 2010. PMID 21204297
  9. Sackmann-Sala L, et al. Activation of the GH/IGF-1 axis by CJC-1295 results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res 2009. PMID 19386527
  10. World Anti-Doping Agency: Prohibited List 2026 (copy hosted by SEGAS). segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf

Sources

Administration & storage

Administration
Subcutaneous injection in human clinical trials (PMID: 16352683)Subcutaneous injection in rat studies (PMID: 15817669)Intravenous administration in rat pharmacokinetic/metabolism studies (PMID: 26879649)Injection route not further specified in some human studies (PMID: 1701865419386527)
Storage
The reviewed abstracts do not describe storage conditions for CJC-1295. One anti-doping study noted that urine samples containing GHRH analogues (including CJC-1295) should be handled properly to avoid degradation, with sermorelin and its metabolite found to rapidly degrade at temperatures >4 °C and pH values <7; stability of CJC-1295 itself under those conditions was not separately quantified.
Cautions
CJC-1295 is not approved by any regulatory authority for performance enhancement or general clinical use; human safety data beyond short-term pharmacokinetic studies are lacking.,Potential adverse effects associated with GH-axis modulation (including prolactin/cortisol elevations, appetite changes, dysglycaemia, fluid retention, myalgia/arthralgia, and injection-site reactions) have been reported in the context of GH-axis peptides in this class; specific long-term safety data for CJC-1295 are not available from the reviewed literature.,Products sold outside regulated channels may be mislabelled or contaminated; an illicitly manufactured pharmaceutical preparation containing CJC-1295 was identified by Norwegian police and customs authorities in 2009.,CJC-1295 is classified as a prohibited substance by WADA; use by competitive athletes carries significant anti-doping consequences.,Sterile technique is essential for any injectable compound to minimise infection risk.

Legal & regulatory status

US FDA

Not approved by the FDA for any indication. Classified as a prohibited performance-enhancing substance by WADA. (PMID: 41966639, 41880199, 31849 — see WADA status below)

WADA

Prohibited by the World Anti-Doping Agency (WADA) under Section S2 of the Prohibited List as a growth hormone-releasing hormone analogue.

Health Canada

Not stated in reviewed literature — requires manual verification